Skip To Main Content
Lilly
Menu closed
Lilly
  • Account Login / Register
  • Medical Home
    • Medical Information
  • Medical Education
  • Science
Ask Lilly

We're here to help.

Chat
Chat with us Chat with us
Question Contact Us
Expand contact lilly
Lilly

You are now leaving the LillyMedical.com website

The link you clicked on will take you to a site maintained by a third party, which is solely responsible for its content. Lilly USA, LLC does not control, influence, or endorse this site, and the opinions, claims, or comments expressed on this site should not be attributed to Lilly USA, LLC. Lilly USA, LLC is not responsible for the privacy policy of any third-party websites. We encourage you to read the privacy policy of every website you visit.
Click "Continue" to proceed or "Return" to return to LillyMedical.com.

  1. Medical Information Right
  2. Diabetes Right
  3. Mounjaro™ (tirzepatide) injection Right
  4. How should tirzepatide doses be increased?
Search Mounjaro (tirzepatide) injection (type in keywords)
Search Medical Information

If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)

Loading icon

Mounjaro™ (tirzepatide) injection

2.5 mg/5 mg/7.5 mg/10 mg/12.5 mg/15 mg

Full Prescribing Information

This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.

How should tirzepatide doses be increased?

Tirzepatide should be initiated at 2.5 mg subcutaneously once weekly and increased in 2.5 mg increments every 4 weeks until target dose is achieved, up to a maximum dose of 15 mg.

US_cFAQ_TZP003_DOSE_ESCALATION
US_cFAQ_TZP003_DOSE_ESCALATION
en-US

See important safety information, including boxed warning, in the attached prescribing information.

Dose Escalation

Tirzepatide is a glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes (T2D) for once-weekly, subcutaneous administration.1

Approved Dosing

The recommended starting dose of tirzepatide is 2.5 mg injected subcutaneously once weekly. The 2.5 mg dosage is for treatment initiation and is not intended for glycemic control.1

After 4 weeks, increase the dose to 5 mg once weekly.1

If additional glycemic control is needed, increase the dosage in 2.5 mg increments after at least 4 weeks on the current dose.1

The maximum dose of tirzepatide is 15 mg once weekly.1

Administer tirzepatide

  • once weekly
  • any time of day, and
  • with or without food.1

Tirzepatide should be injected subcutaneously in the abdomen, thigh, or upper arm.1

Clinical Studies

In the phase 3 SURPASS studies, participants were assigned to 1 of 3 tirzepatide treatment arms (5, 10, or 15 mg) for assessment of efficacy and safety (Dose Escalation Schedule for Tirzepatide in Phase 3 Clinical Studies).1

Dose Escalation Schedule for Tirzepatide in Phase 3 Clinical Studies2

The starting dose of tirzepatide was 2.5 mg once weekly for 4 weeks and escalated in 2.5 mg increments every 4 weeks until the assigned dose was achieved.2

Dose escalation in 2.5 mg increments at 4 week intervals was chosen based on the ability to improve the tolerability profile.2

The 3 tirzepatide doses (5, 10, and 15 mg) studied for efficacy in the SURPASS phase 3 clinical study program were identified based on the safety, efficacy, and exposure response modeling of data in participants with T2D in phase 1 and 2 studies.2

Enclosed Prescribing Information

MOUNJARO™ (tirzepatide) injection, for subcutaneous use, Lilly

Reference

The published references below are available by contacting 1-800-LillyRx (1-800-545-5979).

1Mounjaro [package insert]. Indianapolis, IN: Eli Lilly and Company; 2022.

2Conterno E, Yuffa I, Woodward B. Eli Lilly and Company diabetes 2019 business update. Eli Lilly and Company. Published June 10, 2019. Accessed March 22, 2021. https://investor.lilly.com/static-files/a5dbe9fa-f45f-41ef-bc16-bc12be6dd606

Date of Last Review: May 14, 2022

Are you satisfied with this content?

Can't find what you're looking for? Contact us for answers to your medical questions.

  • Copyright
  • Terms of Use
  • Privacy Statement
  • Accessibility Statement
  • Sitemap

    This site is intended for US Healthcare Professionals only.

    4.0.17 02/2023 | GLOOTH00001 04/2015 | © Lilly USA, LLC 2023. All rights reserved.

    Product names listed above are trademarks or registered trademarks owned by or licensed to Eli Lilly and Company, its subsidiaries, or affiliates

    facebook twitter linkedin
    visit www.phactmi.org
    Lilly